Harvard Bioscience (HBIO) Common Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Common Equity data on file, last reported at $10.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $10.0 million, down 32.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (down 32.28% YoY), and the FY2025 annual result was $13.7 million, down 78.32% from the prior year.
• Common Equity eased to $10.0 million in Q1 2026 per HBIO's latest filing, from $13.7 million in the prior quarter.
• Over five years, Common Equity peaked at $77.5 million in Q2 2022 and troughed at $10.0 million in Q1 2026.
• A 5-year average of $54.6 million and a median of $68.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity climbed 3.21% in 2023, then slumped 78.46% in 2025.
• A 5-year view of Common Equity shows it stood at $72.2 million in 2022, then advanced by 1.18% to $73.1 million in 2023, then slipped by 13.32% to $63.3 million in 2024, then sank by 78.32% to $13.7 million in 2025, then slipped by 26.85% to $10.0 million in 2026.
• Business Quant data shows HBIO's Common Equity at $10.0 million in Q1 2026, $13.7 million in Q4 2025, and $14.1 million in Q3 2025.